Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 5
1983 7
1984 15
1985 17
1986 10
1987 15
1988 11
1989 9
1990 4
1991 7
1992 10
1993 11
1994 3
1995 9
1996 6
1997 5
1998 4
1999 8
2000 6
2001 14
2002 6
2003 12
2004 19
2005 10
2006 13
2007 14
2008 7
2009 6
2010 9
2011 6
2012 9
2013 16
2014 6
2015 14
2016 19
2017 9
2018 8
2019 8
2020 3
2021 7
2022 6
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

359 results
Results by year
Filters applied: . Clear all
Page 1
Drug-induced mitochondrial dysfunction and cardiotoxicity.
Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Varga ZV, et al. Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18. Am J Physiol Heart Circ Physiol. 2015. PMID: 26386112 Free PMC article. Review.
In many cases, toxicity problems appear only in the presence of additional cardiovascular disease conditions or develop months/years following the exposure, making the diagnosis difficult. Cardiotoxic agents affecting mitochondria include several widely used anticancer dru …
In many cases, toxicity problems appear only in the presence of additional cardiovascular disease conditions or develop months/years followi …
An application of p-sulfonatocalix[6]arenes to attenuate cardiotoxicity of mitoxantrone in vitro: preparation, characterization and evaluation.
Yu X, Wang M, Wang H, Ren X, Jiang M, Zhu Y, Zhang D. Yu X, et al. J Pharm Pharmacol. 2022 Jan 5;74(1):41-56. doi: 10.1093/jpp/rgab154. J Pharm Pharmacol. 2022. PMID: 34986225
OBJECTIVES: In this study, p-sulfonatocalix[6]arenes (SCA6) was proposed to construct a host-guest complexation to carry mitoxantrone (MIT) to maintain its anti-proliferation effect on HepG2 cells as well as to attenuate cardiotoxicity on H9C2 cells as a nano-size d …
OBJECTIVES: In this study, p-sulfonatocalix[6]arenes (SCA6) was proposed to construct a host-guest complexation to carry mitoxantrone …
Mitoxantrone, More than Just Another Topoisomerase II Poison.
Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM. Evison BJ, et al. Med Res Rev. 2016 Mar;36(2):248-99. doi: 10.1002/med.21364. Epub 2015 Aug 19. Med Res Rev. 2016. PMID: 26286294 Review.
A comprehensive overview of the drug's molecular, biochemical, and cellular pharmacology is presented here, beginning with the cardiotoxic nature of its predecessor doxorubicin and how these properties shaped the pharmacology of mitoxantrone itself. ...Here, we cons …
A comprehensive overview of the drug's molecular, biochemical, and cellular pharmacology is presented here, beginning with the cardiotoxi …
Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review.
van Dalen EC, van der Pal HJ, Bakker PJ, Caron HN, Kremer LC. van Dalen EC, et al. Eur J Cancer. 2004 Mar;40(5):643-52. doi: 10.1016/j.ejca.2003.12.006. Eur J Cancer. 2004. PMID: 15010064 Review.
Mitoxantrone is believed to maintain anthracycline antitumour activity but be associated with a reduced cardiotoxicity. The aim of this study was to evaluate the evidence for the cumulative incidence of and risk factors for mitoxantrone-induced cardiotoxic …
Mitoxantrone is believed to maintain anthracycline antitumour activity but be associated with a reduced cardiotoxicity. The ai …
Subchronic administration of mitoxantrone and the influence of enzyme inhibitors on its induced cardiotoxicity in mice: role of NRF-2/CYP2E1.
Emeka PM, Ibrahim HIM, Alhaider IA, Morsy MA, Mohamed ME. Emeka PM, et al. Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):7806-7822. doi: 10.26355/eurrev_202112_27627. Eur Rev Med Pharmacol Sci. 2021. PMID: 34982442 Free article.
OBJECTIVE: Mitoxantrone (MTX)- induced cardiotoxicity is a clinical concern that is limiting its use. ...CONCLUSIONS: Therefore, agents that inhibit CPY2E1 expression might attenuate MTX-induced cardiotoxicity by increasing NRF-2 expression....
OBJECTIVE: Mitoxantrone (MTX)- induced cardiotoxicity is a clinical concern that is limiting its use. ...CONCLUSIONS: Therefor …
The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity.
Rossato LG, Costa VM, de Pinho PG, Arbo MD, de Freitas V, Vilain L, de Lourdes Bastos M, Palmeira C, Remião F. Rossato LG, et al. Arch Toxicol. 2013 Oct;87(10):1809-20. doi: 10.1007/s00204-013-1040-6. Epub 2013 Apr 2. Arch Toxicol. 2013. PMID: 23545721
Mitoxantrone (MTX) is an antitumor agent that causes cardiotoxicity in 18 % patients. ...
Mitoxantrone (MTX) is an antitumor agent that causes cardiotoxicity in 18 % patients. ...
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
Damiani RM, Moura DJ, Viau CM, Brito V, Morás AM, Henriques JAP, Saffi J. Damiani RM, et al. Toxicol In Vitro. 2018 Oct;52:203-213. doi: 10.1016/j.tiv.2018.06.013. Epub 2018 Jun 15. Toxicol In Vitro. 2018. PMID: 29913208
Doxorubicin (DOX) and Mitoxantrone (MTX) are very effective drugs for a range of tumors despite being highly cardiotoxic. ...In reference of MTX, data regarding PARP-1 overactivation as the mechanism responsible for cardiotoxicity is difficult to find. The ai …
Doxorubicin (DOX) and Mitoxantrone (MTX) are very effective drugs for a range of tumors despite being highly cardiotoxic. ...I …
Inflammation as a Possible Trigger for Mitoxantrone-Induced Cardiotoxicity: An In Vivo Study in Adult and Infant Mice.
Reis-Mendes A, Dores-Sousa JL, Padrão AI, Duarte-Araújo M, Duarte JA, Seabra V, Gonçalves-Monteiro S, Remião F, Carvalho F, Sousa E, Bastos ML, Costa VM. Reis-Mendes A, et al. Pharmaceuticals (Basel). 2021 May 26;14(6):510. doi: 10.3390/ph14060510. Pharmaceuticals (Basel). 2021. PMID: 34073506 Free PMC article.
Mitoxantrone (MTX) is a pharmaceutical drug used in the treatment of several cancers and refractory multiple sclerosis (MS). Despite its therapeutic value, adverse effects may be severe, namely the frequently reported cardiotoxicity, whose mechanisms need further re …
Mitoxantrone (MTX) is a pharmaceutical drug used in the treatment of several cancers and refractory multiple sclerosis (MS). Despite …
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H. Kingwell E, et al. Neurology. 2010 Jun 1;74(22):1822-6. doi: 10.1212/WNL.0b013e3181e0f7e6. Epub 2010 Apr 28. Neurology. 2010. PMID: 20427751 Free PMC article.
BACKGROUND: Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity and other laboratory measures, prevail. ...CONCLUSIONS: Based on cardiac and laboratory assessments, mitoxantrone was reasonably well …
BACKGROUND: Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity a …
Mitoxantrone in progressive multiple sclerosis: when and how to treat?
Gonsette RE. Gonsette RE. J Neurol Sci. 2003 Feb 15;206(2):203-8. doi: 10.1016/s0022-510x(02)00335-0. J Neurol Sci. 2003. PMID: 12559512 Review.
Mitoxantrone (MX) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with worsening relapsing-remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). ...To reduce the risk of cardiac events, the drug should be administer …
Mitoxantrone (MX) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with worsening relapsing- …
359 results